Formed in Ontario and named after the province’s official flower, Trillium grandiflorum, Trillium Therapeutics is an immuno-oncology company targeting CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a “don’t eat me” signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. By blocking this “don’t eat me” signal with decoy receptors, we aim to unmask tumor cells and make them visible to the immune system. As a leading CD47-focused company, Trillium Therapeutics has two decoy receptors (TTI-621 and TTI-622) that are currently being evaluated in patients with hematological malignancies and solid tumors.
At the end of 2019, under new leadership, Trillium underwent a transformational program that included corporate reorganization, the creation of a more clinical development-centric organization and strategic re-prioritization to focus on our intravenous products in large hematology-oncology indications and solid tumors. With offices in Cambridge, MA, USA and Mississauga, ON, Canada, Trillium is home to a globally diverse group of people dedicated to improving the lives of cancer patients.
100 Cambridgepark Drive, Suite 510
Cambridge, MA 02140
Tel: +1 857.412.7029
2488 Dunwin Drive
Mississauga, ON L5L 1J9
Tel: +1 416.595.0627
SVP, Corporate Development and Strategy